Symbols / LIXT
LIXT Chart
About
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 25.94M |
| Enterprise Value | 16.21M | Income | -4.13M | Sales | — |
| Book/sh | 0.41 | Cash/sh | 0.51 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | 7.20 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 5.54 |
| Current Ratio | 10.42 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.25 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | -68.32% |
| ROE | -130.06% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 8.70M |
| Shs Float | 5.70M | Short Float | 1.39% | Short Ratio | 1.14 |
| Short Interest | — | 52W High | 6.26 | 52W Low | 0.64 |
| Beta | 0.84 | Avg Volume | 91.85K | Volume | 27.56K |
| Target Price | — | Recom | None | Prev Close | $2.90 |
| Price | $2.98 | Change | 2.76% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$2.97
Latest analyst target
3. DCF / Fair value
$-7.19
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.97
Low
—
High
—
Mean
—
- Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely? - Yahoo Finance Wed, 19 Nov 2025 08
- Lixte Biotechnology stock falls after acquiring UK-based Liora - Investing.com ue, 25 Nov 2025 08
- Experimental ovarian cancer trial doubles the number of patients it will enroll - Stock Titan ue, 23 Dec 2025 08
- Lixte Biotechnology Holdings, Inc. Announces $5 Million Private Placement of Common Stock and Preferred Shares - Quiver Quantitative ue, 01 Jul 2025 07
- Improving the Odds: How LIXTE Biotechnology (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective - Barchart.com hu, 05 Feb 2026 08
- LIXTE Biotechnology (NASDAQ: LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment - The Globe and Mail ue, 10 Feb 2026 08
- Lixte Biotechnology’s $5M Funding Surge: What’s Next? - StocksToTrade hu, 03 Jul 2025 07
- Will LIXT stock split again soon - 2025 Growth vs Value & Step-by-Step Swing Trade Plans - mfd.ru hu, 12 Feb 2026 17
- Lixte Biotechnology Announces New Registered Direct Offering - TipRanks Mon, 22 Dec 2025 08
- symbol__ Stock Quote Price and Forecast - CNN Wed, 27 Mar 2024 14
- Lixte Biotechnology stock falls after $4.3 million direct offering - Investing.com Mon, 22 Dec 2025 08
- Lixte Biotechnology Holdings (NASDAQ: LIXT) Announces $4.3M Registered Direct Offering Priced at Market - The Globe and Mail Wed, 07 Jan 2026 08
- How rising interest rates impact LIXT stock - Wall Street Watch & Fast Exit and Entry Strategy Plans - mfd.ru ue, 10 Feb 2026 13
- FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals - Yahoo Finance hu, 04 Jul 2024 07
- LIXTE Biotechnology Holdings (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK - The Globe and Mail hu, 08 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -3.57M | -5.07M | -6.30M | -6.72M |
| TotalUnusualItems | -3.40K | 1.95K | -3.37K | -1.16K |
| TotalUnusualItemsExcludingGoodwill | -3.40K | 1.95K | -3.37K | -1.16K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -3.59M | -5.09M | -6.31M | -6.73M |
| EBITDA | -3.57M | -5.07M | -6.30M | -6.72M |
| EBIT | -3.57M | -5.07M | -6.30M | -6.72M |
| NetInterestIncome | -9.77K | 1.25K | 2.32K | -6.79K |
| InterestExpense | 16.82K | 16.23K | 8.88K | 7.41K |
| InterestIncome | 7.05K | 17.49K | 11.20K | 626.00 |
| NormalizedIncome | -3.58M | -5.09M | -6.31M | -6.73M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -3.59M | -5.09M | -6.31M | -6.73M |
| TotalExpenses | 3.57M | 5.09M | 6.31M | 6.72M |
| TotalOperatingIncomeAsReported | -3.57M | -5.09M | -6.31M | -6.72M |
| DilutedAverageShares | 2.25M | 1.92M | 1.58M | 1.35M |
| BasicAverageShares | 2.25M | 1.92M | 1.58M | 1.35M |
| DilutedEPS | -1.59 | -2.66 | -3.99 | -5.00 |
| BasicEPS | -1.59 | -2.66 | -3.99 | -5.00 |
| DilutedNIAvailtoComStockholders | -3.59M | -5.09M | -6.31M | -6.73M |
| NetIncomeCommonStockholders | -3.59M | -5.09M | -6.31M | -6.73M |
| NetIncome | -3.59M | -5.09M | -6.31M | -6.73M |
| NetIncomeIncludingNoncontrollingInterests | -3.59M | -5.09M | -6.31M | -6.73M |
| NetIncomeContinuousOperations | -3.59M | -5.09M | -6.31M | -6.73M |
| PretaxIncome | -3.59M | -5.09M | -6.31M | -6.73M |
| OtherIncomeExpense | -3.40K | 1.95K | -3.37K | -1.16K |
| GainOnSaleOfSecurity | -3.40K | 1.95K | -3.37K | -1.16K |
| NetNonOperatingInterestIncomeExpense | -9.77K | 1.25K | 2.32K | -6.79K |
| InterestExpenseNonOperating | 16.82K | 16.23K | 8.88K | 7.41K |
| InterestIncomeNonOperating | 7.05K | 17.49K | 11.20K | 626.00 |
| OperatingIncome | -3.57M | -5.09M | -6.31M | -6.72M |
| OperatingExpense | 3.57M | 5.09M | 6.31M | 6.72M |
| OtherOperatingExpenses | 1.15M | 1.23M | ||
| ResearchAndDevelopment | 726.23K | 898.10K | 1.35M | 1.74M |
| SellingGeneralAndAdministration | 2.85M | 4.19M | 4.96M | 4.98M |
| GeneralAndAdministrativeExpense | 2.85M | 4.19M | 4.96M | 4.98M |
| OtherGandA | 1.24M | 2.03M | 2.41M | 1.96M |
| InsuranceAndClaims | 434.44K | 442.98K | ||
| SalariesAndWages | 1.17M | 1.72M | 2.55M | 3.02M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 2.25M | 2.25M | 1.66M | 1.37M |
| ShareIssued | 2.25M | 2.25M | 1.66M | 1.37M |
| TangibleBookValue | -2.67M | 494.76K | 1.67M | 1.29M |
| InvestedCapital | -2.67M | 494.76K | 1.67M | 1.29M |
| WorkingCapital | 827.22K | 3.99M | 5.17M | 4.79M |
| NetTangibleAssets | 827.22K | 3.99M | 5.17M | 4.79M |
| CommonStockEquity | -2.67M | 494.76K | 1.67M | 1.29M |
| PreferredStockEquity | 3.50M | 3.50M | 3.50M | 3.50M |
| TotalCapitalization | 827.22K | 3.99M | 5.17M | 4.79M |
| TotalEquityGrossMinorityInterest | 827.22K | 3.99M | 5.17M | 4.79M |
| StockholdersEquity | 827.22K | 3.99M | 5.17M | 4.79M |
| RetainedEarnings | -52.07M | -48.48M | -43.39M | -37.08M |
| AdditionalPaidInCapital | 49.39M | 48.98M | 45.06M | 38.37M |
| CapitalStock | 3.50M | 3.50M | 3.50M | 3.50M |
| CommonStock | 225.00 | 225.00 | 166.00 | 1.37K |
| PreferredStock | 3.50M | 3.50M | 3.50M | 3.50M |
| TotalLiabilitiesNetMinorityInterest | 318.28K | 313.86K | 395.76K | 302.93K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 318.28K | 313.86K | 395.76K | 302.93K |
| CurrentDeferredLiabilities | 235.08K | 157.10K | 165.02K | 76.96K |
| CurrentDeferredRevenue | 235.08K | 157.10K | 165.02K | 76.96K |
| PayablesAndAccruedExpenses | 83.21K | 156.76K | 230.73K | 225.97K |
| Payables | 156.76K | 230.73K | 225.97K | |
| DuetoRelatedPartiesCurrent | 36.25K | 46.98K | ||
| AccountsPayable | 120.51K | 183.75K | 225.97K | |
| TotalAssets | 1.15M | 4.31M | 5.56M | 5.09M |
| TotalNonCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.15M | 4.31M | 5.56M | 5.09M |
| OtherCurrentAssets | 10.38K | 10.25K | ||
| PrepaidAssets | 106.55K | 105.13K | 207.59K | 259.27K |
| CashCashEquivalentsAndShortTermInvestments | 1.04M | 4.20M | 5.35M | 4.82M |
| CashAndCashEquivalents | 1.04M | 4.20M | 5.35M | 4.82M |
| CashFinancial | 1.04M | 4.20M | 5.35M | 4.82M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -3.16M | -4.29M | -4.61M | -4.14M |
| IssuanceOfCapitalStock | 0.00 | 3.14M | 5.14M | 3.69M |
| InterestPaidSupplementalData | 16.82K | 16.23K | 8.88K | 7.41K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 1.04M | 4.20M | 5.35M | 4.82M |
| BeginningCashPosition | 4.20M | 5.35M | 4.82M | 5.07M |
| ChangesInCash | -3.16M | -1.15M | 529.65K | -245.52K |
| FinancingCashFlow | 0.00 | 3.14M | 5.14M | 3.90M |
| CashFlowFromContinuingFinancingActivities | 0.00 | 3.14M | 5.14M | 3.90M |
| NetOtherFinancingCharges | -10.47K | |||
| ProceedsFromStockOptionExercised | 0.00 | 6.32K | 0.00 | 218.10K |
| NetCommonStockIssuance | 0.00 | 3.14M | 5.14M | 3.69M |
| CommonStockIssuance | 0.00 | 3.14M | 5.14M | 3.69M |
| OperatingCashFlow | -3.16M | -4.29M | -4.61M | -4.14M |
| CashFlowFromContinuingOperatingActivities | -3.16M | -4.29M | -4.61M | -4.14M |
| ChangeInWorkingCapital | 3.01K | 20.56K | 154.76K | -13.44K |
| ChangeInOtherWorkingCapital | 77.98K | -7.92K | 88.06K | 61.20K |
| ChangeInPayablesAndAccruedExpense | -73.55K | -73.98K | 2.32K | 35.67K |
| ChangeInPayable | 35.67K | |||
| ChangeInAccountPayable | 35.67K | |||
| ChangeInPrepaidAssets | -1.42K | 102.46K | 64.38K | -110.31K |
| ChangeInReceivables | 0.00 | |||
| StockBasedCompensation | 418.42K | 773.20K | 1.55M | 2.60M |
| NetIncomeFromContinuingOperations | -3.59M | -5.09M | -6.31M | -6.73M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for LIXT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|